Pancreatic Cancer

Potential to extend survival and improve quality of life for pancreatic cancer patients.

ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary. The results described herein may not be predictive.

Thank you for your interest in ViewRay MRIdian SMART (MR-guided stereotactic adaptive radiation therapy). As you may have read, results from 148 inoperable pancreatic cancer patients treated with ablative doses with MRIdian SMART (MR-guided stereotactic adaptive radiation therapy) were presented as part of the Annual Meeting of the American Society for Radiation Oncology (ASTRO), the world’s largest radiation oncology society, held October 24-27, 2021 in Chicago.

The results, presented on October 27 by Michael Chuong, M.D., medical director of radiation oncology at the Miami Cancer Institute, part of Baptist Health South Florida, demonstrated improvement in overall survival and quality of life. Findings showed longer median survival of 26 months compared to 12-15 months typically seen in patients receiving chemotherapy and standard radiation therapy. The 2-year overall survival was over 50 percent, which is more than double the expected 2-year rate of 20 percent with lower dose radiation. The complete press release is available here.

ViewRay is a medical device manufacturer and cannot and does not recommend specific treatment approaches. Individual results may vary. The results described herein may not be predictive.

ViewRay MRIdian SMART Centers Treating Pancreatic Cancer

There are 20 MRIdian SMART centers in the United States located in many major metropolitan areas and 46 worldwide. Detailed contact information for all MRIdian SMART Centers is available here. Please contact your nearest facility to learn more, call us at (440) 703-3210, or complete our contact us form if you need further assistance.


Inoperable: Ken’s Pancreas Cancer
Henry Ford Cancer Institute – Cottage – Detroit, MI


Targeted Therapy Gives New Hope to Pancreatic Cancer Patients
Miami Cancer Institute, Baptist Health South Florida – Miami, FL


Moffitt Cancer Center – MRI-Guided Patient Education Video
H. Lee Moffitt Cancer Center – Tampa, FL

For Clinicians
Pancreatic cancer is among the deadliest types of cancer. While the incidence is comparatively low—it’s the twelfth most common type of cancer diagnosed worldwide1—mortality is high, with most patients succumbing to their disease within one year of diagnosis.2

Today, MRIdian is changing the paradigm for pancreatic cancer treatment.

  • MRIdian may be an option for patients who otherwise may not be offered treatment.3,4,5
  • Treatment may be completed in just five sessions of radiation therapy.3,4,5
  • Potential to extend survival, reduce toxicity and improve quality of life.3,4,5

Learn about the benefits experienced by our MRIdian customers and their patients.

1Ferlay, J., et al. (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Retrieved August 30, 2019 from https://gco.iarc.fr/today

2United European Gastroenterology. (2018). Pancreatic cancer across Europe: Taking a united stand. Retrieved May 5, 2020 from https://www.spg. pt/wp content/uploads/2018/11/Pancreatic_Cancer_Report.pdf

3Rudra, S., Jiang, N., Rosenberg, S. A., Olsen, J. R., Roach, M. C., Wan, L., et al. (2019). Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Medicine, 8(5), 2123–2132. ​

4Herman, J. M., Chang, D. T., Goodman, K. A., Dholakia, A. S., Raman, S. P., Hacker-Prietz, A., et al. (2015). Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer, 121(7), 11281137.

5de Gues, S. W. L., Eskander, M. F., Kasumova, G. G., Ng, S., C., Kent, T. S., Mancias, J. D., et al. (2017). Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer, 123(21), 4158-4167.

Important Safety Information

Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.

Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.

Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.

Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.

Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.

MRIdian Radiation Therapy for Pancreatic Cancer

Key Clinical Study

Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer

A retrospective study at five MRIdian centers showed that high-dose adaptive treatment improves overall survival and eliminates serious toxicity in patients with pancreatic cancer.

Ongoing Clinical Study

Stereotactic MRI-Guided On-Table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastrointestinal toxicity.

The goal of the proposed trial is to investigative in a controlled, prospective manner the robustness of this outcome, and to track quality of life over a 5-year trial period.

Eligible Participants
Patients with borderline resectable or inoperable locally advanced pancreatic cancer who are 18 years and older and meet the inclusion and exclusion criteria noted within the study description.

Trial Design
In this single-arm study, participants will receive radiation therapy using integrated magnetic resonance imaging (ViewRay’s MRIdian MR-Guided Radiation Therapy System) at a dose of 50 Gray in 5 fractions (treatment sessions). Fractions will be delivered at least twice per week and with at least 18 hours between treatments. Each participant will be aligned in the treatment system with MRI-guidance. On-table adaptive replanning will be used when clinically indicated. In all patients, real-time MR-imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam, as necessary.

Outcome Measures
The primary outcome measure of the study is grade 3 or higher gastrointestinal toxicity in the first 90 days after treatment. Secondary measures include overall survival at two years, distant progression-free survival at six months, and changes in patient-reported quality of life (pre-treatment to 12 months post-treatment and for longer periods up to five years).

For more information about trial design, inclusion and exclusion criteria, and trial locations visit https://clinicaltrials.gov/ct2/show/NCT03621644.

Videos Related To Pancreatic Cancer

Patient Story: John Hadley, Pancreatic Cancer

Patient Story: John Hadley, Pancreatic Cancer
Pancreatic Cancer Patient John Hadley and his son-in-law Dave Vincent, former CEO of Gamma West, share John’s story of MRIdian treatment and how he beat the disease.

 

February 1, 2021

Patient Story: Tom Tassie, Pancreatic Cancer

Pancreatic Cancer Patient Tom Tassie shares his story of MRIdian treatment and how he beat the statistics shared with him by his first clinician.

September 22, 2020

Patient Story: Michael Vaquero, Pancreatic Cancer

August 13, 2020

ViewRay MRIdian for Prostate, Breast, and Pancreatic Cancer Treatment

October 22, 2019

MRI-Guided Radiation Therapy Panel

Radiation oncology experts from across the country gathered to discuss the potential of MRI-guided radiotherapy.

Miami Cancer Institute, Baptist Health South Florida

September 28, 2018

October 8, 2018

Recent Pancreatic Cancer Webinar

Pancreatic Cancer in 2020: Surgery and Radiotherapy at the Cutting Edge

Join us for a multi-disciplinary, multi-institutional webinar uniting some of the best and brightest minds in pancreatic cancer care from the U.S. and U.K. We’ll hear from experts committed to advancing care, offering new treatment options, extending life, and improving quality of life for patients and their families battling this deadly disease.

Scientific Presentations Related To Pancreatic Cancer

MRIdian Solutions for Pancreas Cancer; Dr. Michael Chuong, Miami Cancer Institute

MR-Guided SBRT for Pancreas with On-Table Adaptation on MRIdian – MCI Experience

Michael Chuong, MD
Miami Cancer Institute, Baptist Health South Florida
ASTRO 2019

Dr. Chuong has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

SMART: Status Update on the First Prospective, Multi-Institutional Study on Ablative Pancreas SBRT

Parag Parikh, MD
Henry Ford Health System
ASTRO 2019

Dr. Parikh has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

 

Quantitative Radiomics of Daily 0.35T MR Images for Prediction of Tumor Response in Pancreas and Liver

John Chetley Ford, PhD
Sylvester Comprehensive Cancer Center, University of Miami Health System
ASTRO 2018

Dr. Ford has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

High Dose, On-Table, Adaptive Radiation Therapy for Pancreatic Cancer: Encouraging Early Results

Michael Bassetti, M.D., Ph.D. | Assistant Professor, Radiation Oncology
University of Wisconsin, Carbone Cancer Center
Miami Symposium (2018)

Dr. Bassetti has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Improving Pancreatic Cancer Survival by using MR Guided Adaptive Radiation

Parag Parikh, BSE, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine – St. Louis, MO
ASTRO 2017

Dr. Parikh has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

From Anatomical to Functional-based MR Guided Adaptive Radiotherapy: The UCLA Experience

Percy Lee, MD
UCLA Health, Jonsson Comprehensive Cancer Center – Los Angeles, CA
ASTRO 2017

Dr. Lee has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Clinical Experience with MR-guided Radiation Therapy for Pancreatic Tumors at VUmc

Anna Bruynzeel, MD, PhD
VUmc – Amsterdam, The Netherlands
ASTRO 2017

Dr. Bruynzeel has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.

Daily Adaptive Planning for Pancreatic Cancer

Frank Lagerwaard, MD
VUmc – Amsterdam, The Netherlands
ASTRO 2017

Dr. Lagerwaard has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Considerations and Challenges of MR Guided RT

John Bayouth, PhD
Carbone Cancer Center, University of Wisconsin – Madison, WI
ESTRO 37 (2018)

Dr. Bayouth has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

About MRIdian

The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.

Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.

Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.

Results of treatment presented in the videos on this webpage are not indicative of typical or future results. Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.

  Global Info

CUSTOMER LOGIN

Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In
   

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy

Accept